Canadian clinical-stage pharmaceutical company Tryp Therapeutics has collaborated with Clinlogix, a Contract Research Organization (CRO) to receive clinical development support for Tryp’s Psilocybin-for-Neuropsychiatric Disorders (PFNTM) program in the form of medical writing, biostatistical analysis, data management, and trial monitoring.

The collaboration will commence with Clinlogix assisting the company in its upcoming Phase 2a clinical trials for eating disorders such as binge eating and hypothalamic obesity as well as fibromyalgia, a musculoskeletal pain that is accompanied by fatigue, sleep, memory, and mood issues. 

The company also collaborated with Fluence, a psychedelic-based educational platform, on May 3, 2021, to provide psychotherapeutic training for health professionals that are administering psychedelic compounds to patients in Tryp’s Phase 2a clinical trials and design psychotherapy protocols for the treatment.

Founded in 2019, Tryp Therapeutics is a pharmaceutical company focused on developing therapeutics for rare and neuropsychiatric diseases. The company has two drug development programs: 1) a psilocybin-based treatment for certain neuropsychiatric disorders such as fibromyalgia, and 2) razoxane (non-psychedelic) for the treatment of soft tissue sarcomas (a rare disease). The company aims to submit more provincial patents for psilocybin-based innovations in 2021.